Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 6/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29319924 | 1.00 | AHCY (0.57) | AHCYADORA2BP2RY1ADORA3ENPP1 | |
| SCHEMBL22399999 | 0.89 | AHCY (0.73) | AHCYADORA2BP2RY1ADORA3 | |
| SCHEMBL19503479 | 0.89 | AHCY (0.73) | AHCYADORA2BP2RY1ADORA3 | |
| SCHEMBL19503898 | 0.89 | AHCY (0.73) | AHCYADORA2BP2RY1ADORA3 | |
| SCHEMBL19503474 | 0.89 | AHCY (0.49) | AHCYP2RY1ADORA3ENPP1P2RY12 | |
| SCHEMBL16290177 | 0.88 | AHCY (0.56) | AHCYADORA2BP2RY1ENPP1P2RY12 | |
| SCHEMBL12330956 | 0.88 | AHCY (0.56) | AHCYADORA2BP2RY1ENPP1P2RY12 | |
| SCHEMBL29319896 | 0.83 | PDE4D (0.62) | AHCYADORA2BADORA3PNPLMNA | |
| SCHEMBL9311442 | 0.81 | AHCY (0.83) | AHCYADORA2BPNPLMNATP53 | |
| SCHEMBL19503889 | 0.78 | P2RY1 (0.47) | P2RY1ENPP1P2RY12LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091791-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-10765693-B2 | Polymorphic compounds and uses thereof | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2020-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10765693-B2 | Polymorphic compounds and uses thereof | HLA-DRB1, HLA-C, HLA-B | AHCY 1231/4885ADORA2B 276/4885P2RY1 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.